Welcome to our dedicated page for Evotec SE American Depositary Shares news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec SE American Depositary Shares stock.
Evotec SE, headquartered in Hamburg, Germany, is a leading global drug discovery and development company. Specializing in providing comprehensive solutions to pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations, Evotec is renowned for its extensive capabilities in therapeutic areas such as central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.
Evotec’s core business is divided into two main segments: Shared R&D and Just-Evotec Biologics. The Shared R&D segment, making up approximately 80% of the company's sales, offers drug discovery and manufacturing services on a fee-for-service basis. It also engages in integrated drug discovery collaborations leveraging proprietary, internally-developed assets. Just-Evotec Biologics, accounting for about 20% of sales, provides contract development and manufacturing (CDMO) services for biologics.
With a workforce of over 5,000 employees, Evotec operates 18 production sites mainly across Europe and the United States. In recent years, the company has made significant strides in forming strategic alliances and collaborations, such as the recent partnership with Claris Ventures and Variant Bio, aimed at accelerating the development of innovative therapeutics.
Evotec’s multimodal platform combines cutting-edge technologies, data, and scientific expertise to drive the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. The company’s integrated R&D network includes partnerships with all Top 20 Pharma companies and over 800 biotech companies, academic institutions, and other healthcare stakeholders. This robust network facilitates the co-creation of a world-leading pipeline of over 200 proprietary and co-owned R&D projects, ranging from early discovery to clinical development.
Recent achievements by Evotec include the successful Clinical Trial Application (CTA) for IAMA Therapeutics’ lead program IAMA-6 and the strategic collaboration with Janssen for immune-based therapies. Additionally, Evotec has expanded its relationship with Bristol Myers Squibb in neurodegeneration and targeted protein degradation.
Financially, Evotec has demonstrated resilience despite macroeconomic challenges and a substantial cyber-attack in 2023. The company reported a 4% increase in revenues, reaching €781.4 million in 2023, driven by new collaborations and the strong performance of Just-Evotec Biologics.
As of 2024, Evotec continues to focus on sustainable and profitable growth, optimizing its operations to meet evolving market demands. The company is committed to advancing its mission of discovering and developing effective therapeutics that address unmet medical needs globally.
Evotec SE held its virtual Annual General Meeting (AGM) on June 22, 2022, with 65.68% of registered shareholders participating. All agenda items were adopted, including the election of Camilla Macapili Languille to the Supervisory Board, succeeding Kasim Kutay. The AGM approved the creation of Authorized Capital 2022 amounting to 20% of the share capital and a revised remuneration system for the Management Board, receiving 94.48% approval. The meeting also reaffirmed BDO AG as auditors for the fiscal year 2022.
Exscientia announced positive results from its Phase 1 healthy volunteer study of EXS-21546, a selective A2A receptor antagonist. The study confirmed potency and selectivity with low CNS exposure, supporting a Phase 1b/2 study in patients with high adenosine signature solid tumors, anticipated to start in the second half of 2022. The trial showed dose-dependent effects and was well-tolerated, with only one serious adverse event recorded that resolved without intervention. These findings enhance the potential for EXS-21546 to improve immunomodulatory treatments in cancer therapy.
Evotec SE has announced a strategic drug discovery collaboration with Janssen Pharmaceutica NV to explore novel therapeutic candidates via its TargetAlloMod platform. This partnership aims for high-potential cell surface drug targets within various therapeutic areas. Besides research funding, Evotec stands to gain approximately €210 million per project in success-based milestones and tiered royalties on resultant products. The collaboration highlights Evotec's innovative strengths and commitment to delivering effective therapeutics.
Evotec has announced the acquisition of Rigenerand Srl, a leading cell technology company, for €23 million. This move enhances Evotec's cell therapy platform by integrating high-quality cGMP manufacturing capabilities. Rigenerand, based in Italy, operates a state-of-the-art facility focused on cell therapy manufacturing. While initial revenue contributions are expected to be modest, the acquisition will strengthen Evotec's capabilities to secure new partnerships in the cell therapy sector. Both companies aim to leverage their combined expertise to advance innovative cell therapies.
Evotec and Almirall have formed a strategic multi-target alliance focusing on severe skin diseases including atopic dermatitis and basal cell carcinoma. This collaboration combines Evotec's advanced AI/ML-driven iR&D platform with Almirall's expertise in medical dermatology. Evotec will handle drug discovery and pre-clinical development, while Almirall will oversee clinical development and marketing. The deal includes an undisclosed upfront payment, potential milestone payments of up to €230 million per program, and royalties on net sales.
Evotec SE has announced the extension and expansion of its partnership with Bristol Myers Squibb in the field of targeted protein degradation, originally established in 2018. This eight-year extension aims to develop a robust pipeline of molecular glue degraders. Evotec will utilize its EVO panOmics and EVO panHunter platforms for this endeavor. The company has received an upfront payment of $200 million, with potential total deal value reaching $5 billion, including additional royalties on product sales.
Evotec SE announced an 8-year extension and expansion of its strategic partnership with Bristol Myers Squibb, initially signed in 2018, to develop a pipeline of molecular glue degraders. The collaboration, leveraging Evotec's EVO panOmics and EVO panHunter platforms, includes an upfront payment of $200 million, with the potential for total deal value reaching $5 billion through performance-based payments and royalties on product sales.
Evotec SE will announce its financial results for Q1 2022 on May 11, 2022. A conference call will follow the announcement, providing updates on performance, scheduled for 2:00 PM CEST. Participants can dial in from various countries, including the USA (+1 877 423 0830) and UK (+44 20 3009 2470). An audio webcast will also be available on the company's homepage shortly before the event. Evotec focuses on developing effective therapeutics through innovative technologies, partnering with top pharmaceutical companies and over 800 biotechnology firms.
Evotec SE reported a 23% increase in group revenues for the fiscal year ended December 31, 2021, reaching €618.0 million. Adjusted EBITDA rose to €107.3 million, up 1% from the previous year. The company achieved significant operational milestones, including expanded partnerships and clinical progress. It holds a robust liquidity position with €858.2 million in cash. For 2022, Evotec expects revenues between €700 - 720 million and plans to invest €70 - 80 million in unpartnered R&D to support ongoing growth initiatives.
Evotec has reached a new programme designation within its collaboration with Bristol Myers Squibb (BMY), triggering a US$ 16 million payment. This programme focuses on an antisense-based approach, distinct from previous small molecule projects, and aims to address neurodegenerative diseases. Evotec could also earn royalties and up to US$ 250 million in milestones. The collaboration enhances Evotec's pipeline, which includes the clinical-stage programme EVT8683, ultimately targeting unmet medical needs in treating neurodegeneration.
FAQ
What is the current stock price of Evotec SE American Depositary Shares (EVO)?
What is the market cap of Evotec SE American Depositary Shares (EVO)?
What is Evotec SE?
What are Evotec's main business segments?
Who are Evotec's partners?
What recent collaborations has Evotec entered into?
How many employees does Evotec have?
What are Evotec's key therapeutic areas?
What financial performance did Evotec report in 2023?
What are the future goals of Evotec?
What is Just-Evotec Biologics?
What makes Evotec's platform unique?
